SV

Street Verdict

Analyst Scorecard

A record of what Chandan Taparia said publicly, with the source. Not advice.

“Recommends buying Aurobindo Pharma shares for a target price of ₹1,170, with a stop loss at ₹1,075. The stock has broken out of a falling supply trend-line on the daily chart with a strong bullish candle, and the RSI indicates positive momentum.”

Chandan Taparia’s track record (trackable calls only): 352 graded calls · 95% CI 32–42%

Aurobindo PharmaBullishCalled 12 Sep 2025Graded 08 Oct 2025
Verdict:MISS

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate. No time frame is stated and the call gives both a target and a stop, so it is tracked until a close reaches one of them (rule H6): the target first is a hit, the stop first a miss, and until then it stays open.

No entry price is stated, so the call starts at the first close after it was published.

Target ₹1,170, stop ₹1,075, as stated.

No time frame is stated, so it is tracked until a close reaches ₹1,170 or ₹1,075: there is no fixed window.

The stop ₹1,075 was reached on a close before the target ₹1,170. Miss.

The grader’s working: R4 TARGET_CALL: entered ₹1100.1 on 2025-09-15 (next trading session's close); stop ₹1075 breached at close ₹1070.8 on 2025-10-08. No time frame is stated and the call gives both a target and a stop, so it is tracked until a close reaches one of them (rule H6): the target first is a hit, the stop first a miss, and until then it stays open.

How it played out

How this is worked out
Target or stop first
The stop was reached on a close before the target was.
Time to target
The target was not reached on a close before the stop was.
Worst close against it
The closing price went as far as 2.66% against the call up to 8 Oct 2025, when the call was decided, measured from the entry price. Closing prices only; an intraday dip is never counted.

From the entry the grade used, on closing prices. This is a record of one past call and is not advice.

Tracking Aurobindo Pharma since this call

1-year tracking window
Read the original articleSee Chandan Taparia’s full track record